Menu
Search
|

Menu

Close
X

Neos Therapeutics Inc NEOS.OQ (NASDAQ Stock Exchange Global Market)

2.74 USD
+0.00 (+0.00%)
As of Mar 18
chart
Previous Close 2.74
Open 2.54
Volume 142,342
3m Avg Volume 118,280
Today’s High 2.87
Today’s Low 2.45
52 Week High 9.20
52 Week Low 1.41
Shares Outstanding (mil) 28.08
Market Capitalization (mil) 255.53
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY18
50
FY17
27
FY16
9
EPS (USD)
FY18
-1.676
FY17
-2.760
FY16
-5.190
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.54
Price to Sales (TTM)
vs sector
16.36
8.39
Price to Book (MRQ)
vs sector
9.83
5.27
Price to Cash Flow (TTM)
vs sector
--
24.12
Total Debt to Equity (MRQ)
vs sector
260.80
16.02
LT Debt to Equity (MRQ)
vs sector
233.06
11.35
Return on Investment (TTM)
vs sector
-84.78
13.82
Return on Equity (TTM)
vs sector
-242.19
15.25

EXECUTIVE LEADERSHIP

Alan Heller
Chairman of the Board, Since 2009
Salary: --
Bonus: --
Gerald McLaughlin
President, Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
Richard Eisenstadt
Chief Financial Officer, Since 2014
Salary: $187,692.00
Bonus: $77,627.00
Dorothy Engelking
Vice President of Regulatory Affairs, Since 2010
Salary: --
Bonus: --
Beth Hecht
Director, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

2940 N State Highway 360 Ste 400
GRAND PRAIRIE   TX   75050-6424

Phone: +1972.4081360

Neos Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD). Its product candidates are extended-release (XR), medications in patient-friendly, orally disintegrating tablets (ODT) or liquid suspension dosage forms. Its branded product and product candidates incorporate over two of the prescribed medications for the treatment of ADHD, methylphenidate and amphetamine. Its modified-release drug delivery platform has enabled it to create extended-release ODT and liquid suspension dosage forms of the medications. It focuses on developing Adzenys XR-ODT, Cotempla XR-ODT and NT-0201.

SPONSORED STORIES